Zevra Therapeutics

Denmark - Frederiksberg

Biotechnology

Website LinkedIn Careers Page

Focus: Modifications of Existing Drugs

Zevra Therapeutics is a life sciences company focused on Modifications of Existing Drugs.

Rare Diseases

Open Jobs

16

Products & Portfolio (1)

benzhydrocodone and acetaminophen

hydrocodone. Hydrocodone Hydrocodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of hydrocodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with hydrocodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. Acetaminophen Acetaminophen is a non-opioid, non-salicylate analgesic. The site and mechanism for the analgesic effect of acetaminophen has not been determined but is thought to primarily involve central actions.

Pipeline & Clinical Trials

Sodium phenylbutyrate

Combined D,L-2-hydroxyglutaric Aciduria

Phase 1

Clinical Trials (1)

NCT07125066An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA)

Phase 1

Sodium phenylbutyrate

Medium-chain Acyl-CoA Dehydrogenase Deficiency

Phase 2

Clinical Trials (1)

NCT06773026Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Phase 2

Serdexmethylphenidate

Idiopathic Hypersomnia

Phase 2

Clinical Trials (1)

NCT05668754Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Phase 2

KP415 oral capsule

Phase 3

Clinical Trials (1)

NCT03292952KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

Phase 3

KP415 oral capsule

Phase 3

Clinical Trials (1)

NCT03460652KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

Phase 3

Open Jobs (16)

Executive Assistant to the CEO (Onsite)

Corporate Administration

Rare Disease Specialist

Medical/Senior Medical Science Liaison, Northeast

Medical Affairs

Medical/Senior Medical Science Liaison, Northeast

Medical Affairs

Medical/Senior Medical Science Liaison, South

Medical Affairs

Medical/Senior Medical Science Liaison, South

Medical Affairs

Medical/Senior Medical Science Liaison, Central

Medical Affairs

Medical/Senior Medical Science Liaison, Central

Medical Affairs

Medical/Senior Medical Science Liaison, Northeast

Medical Affairs

Medical/Senior Medical Science Liaison, Northeast

Medical Affairs

Medical/Senior Medical Science Liaison, Central

Medical Affairs

Medical/Senior Medical Science Liaison, South

Medical Affairs

Vice President, Head of Regulatory Affairs

Regulatory Affairs

Medical/Senior Medical Science Liaison, Northeast

Medical Affairs

Vice President, Controller

Director, Patient Advocacy

Medical Affairs

Interview Prep Quick Facts

Portfolio: 1 approved product, 5 clinical trials

Open Roles: 16 active jobs

Portfolio Health

Peak1 (100%)

1 total products

Hiring Trend

Stable

16

Open Roles

+1

Added

-0

Filled/Removed

Based on last 4 crawl cycles